Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

How much is mebendazole?
When did risperdal constas patent expire published article?
Dabrafenib mesylate when the patent is expiring in india?
When does guselkumab patent expire?
Dabrafenib patent expiration?

Erleada discount?

See the DrugPatentWatch profile for Erleada

What is Erleada?


Erleada (apalutamide) is a medication used to treat prostate cancer. Specifically, it is indicated for non-metastatic castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer (CSPC) [1].

How is Erleada Discounted?


Information regarding specific discount programs for Erleada is not publicly detailed in the provided text. However, patient assistance programs are common for prescription medications, which can help reduce out-of-pocket costs for eligible individuals.

Who Offers Patient Assistance for Erleada?


Janssen, the manufacturer of Erleada, typically provides patient assistance programs. These programs are designed to help patients who have commercial insurance but face high out-of-pocket costs, as well as those who are uninsured or underinsured [1]. The specific details and eligibility requirements for these programs can be found on the manufacturer's website or by contacting their patient support services.

What Are the Costs Associated with Erleada?


The cost of Erleada can vary significantly based on insurance coverage, pharmacy, and location. While exact figures are not provided, prescription medications for serious conditions like prostate cancer often represent a substantial financial commitment for patients.

When Does Erleada's Patent Expire?


Patent information for medications is complex and can involve multiple patents covering different aspects of the drug. To determine the specific patent expiration dates for Erleada, one would typically consult specialized databases. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and exclusivity periods, which can provide detailed insights into when patent protection for Erleada is set to expire [2].

---

Sources:

[1] https://www.erleada.com/patient-support
[2] https://drugpatentwatch.com/



Other Questions About Erleada :

erleada patent expiration Us erleada market? Erleada expiry date? Erleada prostate cancer clinical trials? Erleada mechanism of action trial data? Erleada? Erleada clinical trial summaries for providers?

AI-Drug Label Prescribing Information Alignment Report

86
86%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

Indication-related claims match the FDA label (Section 1). Manufacturer/patient assistance program claims are not supported by the provided prescribing information excerpts and cannot be verified from the label text supplied.

Category Scores

Indication
100
Excellent

Accurate Statements

Erleada (apalutamide) is a medication used to treat prostate cancer.
Section 1 (INDICATIONS AND USAGE) indicates ERLEADA is indicated for prostate cancer treatment in specified settings.
Erleada is indicated for non-metastatic castration-resistant prostate cancer (CRPC).
Section 1 (INDICATIONS AND USAGE) lists non-metastatic castration-resistant prostate cancer (nmCRPC).
Erleada is indicated for metastatic castration-sensitive prostate cancer (CSPC).
Section 1 (INDICATIONS AND USAGE) lists metastatic castration-sensitive prostate cancer (mCSPC).

Unsupported Statements

Janssen, the manufacturer of Erleada, typically provides patient assistance programs.
The provided FDA label excerpts (Section 1 and Section 17) do not mention Janssen providing patient assistance programs.
Janssen patient assistance programs for Erleada are designed to help patients who have commercial insurance but face high out-of-pocket costs.
No information about patient assistance program eligibility or design is present in the provided label excerpts.
Janssen patient assistance programs for Erleada are designed to help patients who are uninsured or underinsured.
No information about patient assistance program eligibility or design is present in the provided label excerpts.

Contradictions

Important Omissions

For the indication claim(s), the label also specifies the indication as treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC); no additional missing indication elements are identified in the provided excerpts.
Importance: Low

Safety Assessment

Potential Patient Risk: Low
Indication statements are label-consistent. Unsupported patient assistance program statements could mislead operational/coverage expectations, but they do not directly conflict with safety information in the provided label excerpts.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Patient assistance program claims are not supported by the provided FDA prescribing information excerpts.

Suggested Improvement
Remove or qualify manufacturer/patient assistance claims unless supported by label text or other verifiable, label-consistent sources.

Drug Brand Mention Assessment

Branding Score
23
Visibility
40
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Core Claims
  • Erleada (apalutamide) is a medication used to treat prostate cancer.
  • It is indicated for non-metastatic castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer (CSPC).
  • Information regarding specific discount programs for Erleada is not publicly detailed in the provided text.
  • The cost of Erleada can vary significantly based on insurance coverage, pharmacy, and location.
  • Janssen, the manufacturer of Erleada, typically provides patient assistance programs.
Differentiators
Pricing Perception: Not Mentioned